{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:40:40Z","timestamp":1790214040666,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023503","name":"Department of Psychiatry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023503","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003321","name":"Queen's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.psychres.2024.116125","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:33:02Z","timestamp":1722879182000},"page":"116125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression"],"prefix":"10.1016","volume":"340","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-3737","authenticated-orcid":false,"given":"Gilmar","family":"Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-1395","authenticated-orcid":false,"given":"Jennifer","family":"Swainson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0468-1099","authenticated-orcid":false,"given":"Nisha","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-4669","authenticated-orcid":false,"given":"Raymond W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathy","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kowara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Baskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-5027","authenticated-orcid":false,"given":"Sean Michael","family":"Nestor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody J.Y.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-1438","authenticated-orcid":false,"given":"Aleksandar","family":"Biorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May 2022","key":"10.1016\/j.psychres.2024.116125_bib0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2024.116125_bib0002","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2024.116125_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyab023","article-title":"Ketamine for bipolar depression: a systematic review","author":"Bahji","year":"2021","journal-title":"Internat. J. Neuropsychopharmac."},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0004","first-page":"158","article-title":"Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant","volume":"30","author":"Bahr","year":"2019","journal-title":"P&T - Drug Forecast"},{"issue":"September","key":"10.1016\/j.psychres.2024.116125_bib0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jad.2022.09.083","article-title":"Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates","volume":"319","author":"Brendle","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.psychres.2024.116125_bib0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/0706743719828965","article-title":"Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews","volume":"64","author":"Brown","year":"2019","journal-title":"Canad. J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0007","first-page":"0","article-title":"Common terminology criteria for adverse events","volume":"3","year":"2006","journal-title":"Nat. Cancer Inst."},{"issue":"January","key":"10.1016\/j.psychres.2024.116125_bib0008","first-page":"1","article-title":"Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada","volume":"14","author":"Chrenek","year":"2023","journal-title":"Front. Psychiatry"},{"issue":"November 2019","key":"10.1016\/j.psychres.2024.116125_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jad.2020.03.106","article-title":"Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"271","author":"Citrome","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2024.116125_bib0010","article-title":"Agreement between physicians\u2019 and patients\u2019 ratings on the montgomery-\u00e5sberg depression rating scale","volume":"135","author":"Cunningham","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"December 2023","key":"10.1016\/j.psychres.2024.116125_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jad.2023.12.038","article-title":"The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data","volume":"348","author":"d'Andrea","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"November 2021","key":"10.1016\/j.psychres.2024.116125_bib0012","article-title":"Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: results from the canadian rapid treatment center of excellence","volume":"307","author":"Di Vincenzo","year":"2022","journal-title":"Psychiatry Res."},{"issue":"August","key":"10.1016\/j.psychres.2024.116125_bib0013","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jad.2023.09.030","article-title":"Early effects predict trajectories of response to esketamine in treatment-resistant depression","volume":"342","author":"Estrade","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response implications for large scale study design and clinical development","volume":"35","author":"Frye","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.psychres.2024.116125_bib0015","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.14m09391","article-title":"The predictive validity of the beck depression inventory suicide item","volume":"76","author":"Green","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115865","article-title":"IV low dose ketamine infusions for treatment resistant depression: results from a five-year study at a free public clinic in an academic hospital","volume":"335","author":"Gutierrez","year":"2024","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.psychres.2024.116125_bib0017","first-page":"11","article-title":"Efficacy and tolerability of two novel \u201cstandard of care\u201d treatments-intranasal esketamine versus intravenous ketamine-for treatment-resistant depression in naturalistic clinical practice: protocol for a pilot observational study","author":"Gutierrez","year":"2022","journal-title":"JMIR. Res. Protoc."},{"key":"10.1016\/j.psychres.2024.116125_bib0018","first-page":"2859","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder : a meta-analysis of randomized","author":"Han;","year":"2016","journal-title":"Dovepress"},{"issue":"4","key":"10.1016\/j.psychres.2024.116125_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2836","article-title":"Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression","volume":"37","author":"Jesus-Nunes","year":"2022","journal-title":"Hum. Psychopharmacol."},{"issue":"NOV","key":"10.1016\/j.psychres.2024.116125_bib0020","first-page":"1","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.psychres.2024.116125_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/07067437241245384","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults","author":"Lam","year":"2024","journal-title":"Can. J. Psychiatry"},{"issue":"February","key":"10.1016\/j.psychres.2024.116125_bib0022","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2024.116125_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0702-8","article-title":"Ketamine and beyond : investigations into the potential of glutamatergic agents to treat depression","author":"Lener","year":"2017","journal-title":"Drugs"},{"issue":"September","key":"10.1016\/j.psychres.2024.116125_bib0024","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2024.116125_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2024.116125_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.31887\/DCNS.2011.13.2\/hmoeller","article-title":"Effectiveness studies: advantages and disadvantages","volume":"13","author":"M\u00f6ller","year":"2011","journal-title":"Dialogues. Clin. Neurosci."},{"key":"10.1016\/j.psychres.2024.116125_bib0028","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"Scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British J. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2024.116125_bib0029","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jamapsychiatry.2022.1074","article-title":"Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting","volume":"79","author":"Nikayin","year":"2022","journal-title":"JAMa Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0030","first-page":"22","article-title":"Full information about Oxford ketamine service","volume":"2.1","year":"2022","journal-title":"Intervent. Psychiatry Serv."},{"issue":"4","key":"10.1016\/j.psychres.2024.116125_bib0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-020-00953-4","article-title":"Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression","volume":"60","author":"Perez-Ruixo","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.psychres.2024.116125_bib0032","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0033","series-title":"Ketamine","year":"2021"},{"issue":"November 2020","key":"10.1016\/j.psychres.2024.116125_bib0034","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.119","article-title":"A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions","volume":"282","author":"Rodrigues","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.psychres.2024.116125_bib0035","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/13651501.2022.2030757","article-title":"Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme","volume":"26","author":"Samalin","year":"2022","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"1","key":"10.1016\/j.psychres.2024.116125_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-023-05038-7","article-title":"A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients","volume":"23","author":"Seem\u00fcller","year":"2023","journal-title":"BMC. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2024.116125_bib0037","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"November 2020","key":"10.1016\/j.psychres.2024.116125_bib0038","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpsychires.2021.03.009","article-title":"Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: a systematic review","volume":"137","author":"Siegel","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2024.116125_bib0039","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1037\/1082-989X.6.4.317","article-title":"The use of multiple imputation for the analysis of missing data","volume":"6","author":"Sinharay","year":"2001","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.psychres.2024.116125_bib0041","series-title":"Principal component (PCA) and exploratory factor analysis (EFA) With SPSS","year":"2021"},{"issue":"1","key":"10.1016\/j.psychres.2024.116125_bib0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A","article-title":"Dimensions of the beck depression inventory-ii in clinically depressed outpatients","volume":"55","author":"Steer","year":"1999","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.psychres.2024.116125_bib0043","doi-asserted-by":"crossref","unstructured":"Su, T., Li, C., Lin, W., Wu, H., Tsai, S., Bai, Y.M., Mao, W.C., Tu, P.C., Chen, L.F., Li, W.C., Chen, M.H., 2023. A randomized, double-blind, midazolam-controlled trial of low-dose ketamine infusion in patients with treatment-resistant depression and prominent suicidal ideation. 26, 331\u2013339.","DOI":"10.1093\/ijnp\/pyad014"},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0044","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-022-00897-2","article-title":"Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing","volume":"36","author":"Swainson","year":"2022","journal-title":"CNS. Drugs"},{"issue":"2","key":"10.1016\/j.psychres.2024.116125_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","article-title":"The Canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder","volume":"66","author":"Swainson","year":"2021","journal-title":"Canadian J. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0046","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jad.2021.02.043","article-title":"Evaluation of MADRS severity thresholds in patients with bipolar depression","volume":"286","author":"Thase","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.psychres.2024.116125_bib0047","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/acps.13260","article-title":"Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression","volume":"143","author":"Turkoz","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2024.116125_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.704330","article-title":"Antianhedonic effect of repeated ketamine infusions in patients with treatment resistant depression","volume":"12","author":"Wilkowska","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116125_bib0049","unstructured":"World Health Organization. (2020). Depression. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"10.1016\/j.psychres.2024.116125_bib0050","article-title":"Factors associated with antidepressant effects of ketamine: a reanalysis of double-blind randomized placebo-controlled trial of intravenous ketamine for treatment-resistant depression","author":"Yonezawa","year":"2023","journal-title":"PharmacoPsychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2024.116125_bib0051","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"August","key":"10.1016\/j.psychres.2024.116125_bib0052","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178124004104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178124004104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T21:43:05Z","timestamp":1732225385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178124004104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":52,"alternative-id":["S0165178124004104"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2024.116125","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2024.116125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116125"}}